Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04603846
Other study ID # NTL-LEES-2019-06
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date September 10, 2020
Est. completion date August 25, 2023

Study information

Verified date January 2022
Source Lee's Pharmaceutical Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the safety and efficacy of recombinant anti-PD-L1 monoclonal antibody injection (ZKAB001) combined with Albumin-bound paclitaxel in the treatment of Advanced urothelial carcinoma


Description:

This trial is designed to first include 6 subjects to confirm the dose safety. If the toxicity is intolerable, the dose of chemotherapeutic drugs will be reduced depending on the toxicity for further exploration.If it was tolerated, the recommended dose was determined, and the dose was extended. 14 patients were enrolled to further observe the safety and efficacy.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 20
Est. completion date August 25, 2023
Est. primary completion date October 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years old; - Pathologically confirmed urothelial carcinoma; - Terminal patients who have not received treatment or for the first time recurrence more than 6 months after the end of adjuvant chemotherapy after surgery; - Evaluable lesions based on RECIST V1.1; - ECOG score 0-1; - Estimated life expectancy >3 months; - The function of important organs meets the following requirements; - The subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up. Exclusion Criteria: - Previously received drugs targeting PD-1, PD-L1, PD-L2 or other treatments targeting T cell costimulation or checkpoint channels; - Received systemic corticosteroid immunosuppressants 2 weeks before the study; - Suffer from active meningeal metastasis or uncontrolled, untreated brain metastasis; - Severe cardiovascular disease, such as New York Heart Association (New York Heart Association,NYHA standard) Grade 3-4 heart failure, unstable angina pectoris, unstable arrhythmia, or color heart photo indicates LVEF (left ventricular ejection fraction) < 50%; - Previous hypersensitivity to monoclonal antibodies; - The patient has known, active or suspected autoimmune diseases. The following conditions are allowed: skin diseases that do not require systemic treatment (such as vitiligo, psoriasis), type I diabetes, autoimmune hypothyroidism with hormone replacement therapy; - The study drug suffered from other active malignant tumors within 5 years before the first use of the drug. Cured localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, carcinoma in situ of the cervix, carcinoma in situ of the breast, etc., can be included in the group; - Active hepatitis B or C (unless HBV-DNA titer < 500IU/mL or copy number < 1000copies/ml, HCV-RNA negative after antiviral treatment can be included in), HIV positive or known history of acquired immunodeficiency syndrome; - Severe infection existed before screening, including but not limited to, infections requiring hospitalization, bacteremia, severe pneumonia, etc; - There has been active pulmonary tuberculosis in the past year, whether treated or not; - Live attenuated vaccine was used within 28 days prior to screening; - Patients who have previously received allogeneic bone marrow transplantation or solid organ transplantation; - Have received any other experimental drug treatment within 28 days prior to signing ICF; - Pregnant or lactating women; - Patients of childbearing age who refuse to use effective contraception; - Other researchers believe that it is not suitable to join the group.

Study Design


Intervention

Drug:
anti-PD-L1 antibody
Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.
albumin bound paclitaxel
Patients will receive 6 cycles of albumin bound paclitaxel 260mg/m2 on days 1 every 3 weeks .

Locations

Country Name City State
China Beijing Tumor Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Lee's Pharmaceutical Limited

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose limiting toxicity (DLT) Adverse events of level 3 or above related to the study drug occurring within 21 days after the first dose as assessed by CTCAE v5.0. 21 days after first dose
Primary Recommended phase II dose (RP2D) DLT occurs in no more than 1/6 subjects, this dose is defined as RP2D. 21 days after first dose
Secondary objective response rate Percentage of patients in partial and complete response 12 months
Secondary progression free survival time between first dose of study drug to disease progression 12 months
Secondary PD-L1 expression The positive rate of PD-L1 expression in tumor tissue. 12 months
Secondary TMB expression The positive rate of TMB expression in tumor tissue. 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00365157 - Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Phase 1/Phase 2
Recruiting NCT01487915 - Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma Phase 2
Not yet recruiting NCT04064190 - Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition Phase 2
Not yet recruiting NCT06079112 - 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer Phase 1/Phase 2
Recruiting NCT05544552 - Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations Phase 1/Phase 2
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Active, not recruiting NCT02735252 - PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer N/A
Recruiting NCT05733000 - CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Phase 2
Recruiting NCT05738161 - Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma Phase 1
Completed NCT00942331 - Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Phase 3
Not yet recruiting NCT05687721 - Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer Phase 1/Phase 2
Recruiting NCT04871334 - Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma Phase 1
Not yet recruiting NCT06196736 - A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer Phase 3
Completed NCT02599324 - Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Phase 1/Phase 2
Active, not recruiting NCT04491942 - Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Phase 1
Recruiting NCT05929235 - A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma Phase 1
Recruiting NCT04856189 - Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma Phase 1/Phase 2